Eupraxia Pharmaceuticals (NASDAQ:EPRX) Releases Earnings Results, Misses Estimates By $0.01 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced its earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01), Zacks reports.

Eupraxia Pharmaceuticals Trading Up 2.6%

EPRX traded up $0.19 during midday trading on Tuesday, hitting $7.61. The company’s stock had a trading volume of 114,678 shares, compared to its average volume of 207,401. The firm has a market cap of $459.87 million, a P/E ratio of -7.39 and a beta of 1.19. The firm has a 50-day moving average price of $7.35 and a two-hundred day moving average price of $7.25. Eupraxia Pharmaceuticals has a 52-week low of $3.67 and a 52-week high of $9.32.

Institutional Trading of Eupraxia Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Guardian Wealth Advisors LLC NC acquired a new position in Eupraxia Pharmaceuticals during the 4th quarter worth approximately $76,000. Aptus Capital Advisors LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter valued at approximately $76,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter valued at approximately $71,000. Bank of America Corp DE raised its position in shares of Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after acquiring an additional 10,059 shares in the last quarter. Finally, Geode Capital Management LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter valued at approximately $105,000.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on EPRX. Cantor Fitzgerald increased their price target on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Zacks Research raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a report on Monday, May 4th. William Blair assumed coverage on Eupraxia Pharmaceuticals in a report on Monday, March 23rd. They issued an “outperform” rating for the company. Finally, Wall Street Zen raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.